Fabry's disease pathophysiology

Fabry's disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fabry's disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Fabry's disease pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Fabry's disease pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Fabry's disease pathophysiology
CDC on Fabry's disease pathophysiology
Fabry's disease pathophysiology in the news
Blogs on Fabry's disease pathophysiology
Directions to Hospitals Treating Fabry's disease
Risk calculators and risk factors for Fabry's disease pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sukaina Furniturewala, MBBS[2]

Pathophysiology

Physiology

• GLA gene codes information for the alpha-galactosidase enzyme.
• The normal function of the alpha-galactosidase enzyme is to breakdown globotriaosylceramide (also abbreviated as Gb3, GL-3, or ceramide trihexoside) into glucocerebroside in lysosomes.
• Gb3 is produced in the catabolism pathway of Globoside, an essential glycosphingolipid in the cell membrane (RBCs and Kidney), that is mainly metabolized in the lysosome of the spleen, liver , and bone marrow.

Pathogenesis

• Fabry disease is caused by a deficiency of alpha-galactosidase.
• Mutations to the GLA gene encoding α-GAL may result in complete loss of function of the enzyme.
• Alpha-galactosidase is a lysosomal protein responsible for breaking down globotriaosylceramide(Gb3) a fatty substance stored in various types of cardiac and renal cells
• Improper catabolisation causes globotriaosylceramide (Gb3) to accumulate in cells lining blood vessels in the skin, kidney, heart, and nervous system. As a result, signs, and symptoms of Fabry disease begin to manifest.
• Accumulation of globotriaosylceramide (Gb3) in different tissues leads to cellular death, compromised energy metabolism, small vessel injury, potassium-calcium channel dysfunction in the endothelial cells, oxidative stress,impaired autophagosome maturation, tissue ischemia, irreversible cardiac and renal tissue fibrosis.

Genetics

• Fabry's disease follows an X-linked inheritance pattern.
• Since it is inherited in an X linked pattern, males are homozygous and pass the disease to all daughters but no sons.
• Females are heterozygous with 50% chance of passing the mutated gene to both daughters and sons.
• skewed non random X chromosome inactivation may cause paradoxical nature of the disease that is seen in females, they have a varied presentation from being asymptomatic to having very severe symptoms and having a presentation similar to that seen in males with the classical type
• Gene function: GLA gene encodes information for alpha-Gal-A
• Gene location: GLA has its locus located on the Long arm of chromosome X in position Xq22. It has 7 exons distributed over 12,436 base pairs.
• Demonstrates extensive allelic heterogeneity but no genetic locus heterogeneity.
• 585 mutations have so far been recorded for Fabry's disease.
• Mutations demonstrated include Missense, Non-sense point mutations,splicing mutations, small deletion/Insertion, and large deletions.

Gross pathology

• The most important characteristics of Fabry's disease on gross pathology are:
  • Kidney
    • Kidney enlargement
    • Renal cysts of cortical and parapelvic
    • Decreased cortical thickness
  • Heart
    • Four chamber cardiomegaly( frequently LVH with interventricular septum hypertrophy)
  • Eye
    • Conjunctiva
      • Ampullary and saccular aneurysms of small venules
      • Thrombosis
    • Retina
      • Segmental dilatation and tortuosity of venules and arteries
      • Whorl-like corneal dystrophic pattern

Microscopic pathology

General

On microscopic histopathological analysis, tissue deposition of glycosphingolipids crystalline is a characteristic finding of Fabry's disease.

• Glycosphingolipid inclusions morphology: coarsely lamellated appearance, maybe round with onion-skin likes structure (Myelin figures), or dense unstructured layer (Zebra bodies), some can be dark electrodense and amorphous especially in endothelial and mesangial cells.
• Electron Microscopy: The most accurate method for detection of glycosphingolipids depositions. preserved whole glycosphingolipids during the preparation process.
• Light microscopy is not as specific in confirming FD as electron microscopy and thus is only done when electron microscopy is unavailable.

Light microscopy

Paraffin-embedded sections	H&E staining	Cytoplasm vacuolation (swollen appearance)	Characteristic but not pathognomonic
	Jones methenamine silver (JMS) staining	granular and argyrophilic inclusions	due to the residual carbohydrate part of glycosphingolipids
Methacrylate-embedded sections	Lipid-soluble dye	glycosphingolipids inclusions	not routine
Frozen section	Allows preservation but may lose dome details
Epon-embedded sections	Toluidine blue	dark blue and dark gray round spiral inclusions	detect entire glycosphingolipids
	Methylene blue

• Immunofluorescence Microscopy: Negative, not react to IgG, IgM, IgA, C3, C1q antibodies.
• Immunohistochemistry: Murine anti-Gb3 antibody id used.

Organs

Organs	Light microscope	Electron microscope
Skin (Angiokeratoma)	Hyperkeratosis Hyperplastic epidermis Dilated subepidermal capillaries Moderate dilatation in deep vessels with partially organized fibrinous thrombi Atrophic/Scarce sweat glands Glycosphingolipids is generally small in skin and can be seen particularly in endothelial cells, pericytes and smooth muscle of the cutaneous capillaries, venules and arterioles, fibroblasts and the arrector pilorum muscles, sweat gland epithelium and perineural cells.	large electron-dense glycosphingolipids deposits are seen in endothelial cells, pericytes, and fibroblasts. and also in arrector pilorum muscles and in the secretory, ductal , and myoepithelial cells of eccrine and sweat glands and in the perineural cells, in unmyelinated axons innervating the sweat gland and the small blood vessels around the gland.